EU regulator starts real-time review of Moderna’s COVID-19 vaccine candidate By Reuters

© Reuters. Moderna’s logo is reflected in a drop on a syringe needle in this illustration

(Reuters) – Europe’s health regulator said on Monday it had launched a real-time review of U.S. drugmaker Moderna Inc’s (O:) experimental COVID-19 vaccine, following similar such reviews of rival vaccines from AstraZeneca (L:) and Pfizer (N:).

The European Medicines Agency’s human medicines committee has started a “rolling review” of Moderna’s mRNA-1273 vaccine candidate and is evaluating the first batch of data, the regulator said.

Rolling reviews allow drug companies to submit applications for COVID-19 medicinal products before development work is concluded and prior to the availability of complete supporting documentation, aimed at speeding up any approval process.

In October, Moderna had said it would apply for real-time reviews of its vaccine in Europe.

EMA’s announcement comes a week after Switzerland began a real-time review of data from Moderna’s vaccine candidate.

Moderna said earlier this month that it has enough data for a first interim analysis of its late-stage COVID-19 vaccine trial.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.